1380331-14-5

Upstream product

• 1380331-13-4 (2-phenyl[1,2,4]triazolo[1,5-a]pyridin-7-yl)carbamic acid tert-butyl ester 
• 84249-14-9 2-amino-4-bromopyridine 
• 1202704-61-7 1,2-diamino-4-bromopyridin-1-ium-2,4,6-trimethylbenzenesulfonate 
• 1380331-12-3 7-bromo-2-phenyl-[1,2,4]triazolo[1,5-a]pyridine 
• 461-88-1 pyridine-2,4-diamine 
• 100-47-0 benzonitrile 
• 36016-40-7 mesitylenesulfonylhydroxylamine 

Downstream Products

• 1380330-03-9 1-methyl-5-(2-phenylimidazo[1,2,4]triazolo[1,5-a]pyridin-7-ylcarbamoyl)-1H-pyrazole-4-carboxylic acid ethyl ester 
• 1380329-77-0 1-methyl-5-(2-phenyl[1,2,4]triazolo[1,5-a]pyridin-7-ylcarbamoyl)-1H-pyrazole-4-carboxylic acid 
• 1380329-78-1 4-(azetidine-1-carbonyl)-2-methyl-2H-pyrazole-3-carboxylic acid (2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)amide 
• 1380329-87-2 2-methyl-4-(morpholine-4-carbonyl)-2H-pyrazole-3-carboxylic acid (2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)amide 
• 1380329-88-3 2-methyl-4-(pyrrolidine-1-carbonyl)-2H-pyrazole-3-carboxylic acid (2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-amide 
• 1380329-99-6 4-(3-methoxyazetidine-1-carbonyl)-1-methyl-N-(2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-1H-pyrazole-5-carboxamide 
• 1380330-00-6 4-(3-fluoroazetidine-1-carbonyl)-1-methyl-N-(2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-1H-pyrazole-5-carboxamide 
• 1380330-02-8 isopropyl 1-methyl-5-(2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-7-ylcarbamoyl)-1H-pyrazole-4-carboxylate 
• 1380331-07-6 4-(1,4-diaza-bicyclo[3.2.1]octane-4-carbonyl)-2-methyl-2H-pyrazole-3-carboxylic acid (2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-amide 
• 1380329-97-4 4-(1,1-dioxo-thiomorpholine-4-carbonyl)-2-methyl-2H-pyrazole-3-carboxylic acid (2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-amide 
• 1380331-83-8 1-methyl-5-(2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-7-ylcarbamoyl)-1H-pyrazole-4-carbonyl chloride 
• 1380329-80-5 N₄-ethyl-N₄,1-dimethyl-N₅-(2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-1H-pyrazole-4,5-dicarboxamide 
• 1380329-82-7 N₄-ethyl-1-methyl-N₅-(2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-1H-pyrazole-4,5-dicarboxamide 
• 1380330-25-5 2-methyl-2H-pyrazole-3,4-dicarboxylic acid 4-[methyl-(2,2,2-trifluoro-ethyl)-amide] 3-[(2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-amide] 

Relevant academic research and scientific papers

USE OF A PHOSPHODIESTERASE 10 INHIBITOR FOR THE TREATMENT OF TOURETTE SYNDROME

Provided herein are methods of treating Tourette Syndrome in a subject in need thereof by administering to the subject compositions comprising a PDE10 inhibitor of Formula (I). Also disclosed are crystalline solid forms of the compound of Formula (I) and

PROCESS FOR THE PREPARATION OF 2-PHENYL-[1,2,4]TRIAZOLO[1,5-A]PYRIDINE DERIVATIVES

The invention relates to a novel process for the preparation of 2-phenyl-[1,2,4]triazolo[1,5-a]pyridine derivatives of formula I or of a salt thereof wherein R1 stands for hydrogen, a halogen, for an optionally protected hydroxyl group or for an optionally protected amino group and R2 is hydrogen or a halogen. 2-Phenyl-[1,2,4]triazolo[1,5-a]pyridine derivatives of formula I with their 1,2,4-triazole nucleus build the structural core of a great number of functionalized molecules in medicinal chemistry.

PROCESS FOR THE PREPARATION OF 2-PHENYL-[1,2,4]TRIAZOLO[1,5-A]PYRIDINE DERIVATIVES

The invention relates to a novel process for the preparation of 2-phenyl-[1,2,4]triazolo[1,5- a]pyridine derivatives of formula I or of a salt thereof wherein R1 stands for hydrogen, a halogen, for an optionally protected hydroxyl group or for an optionally protected amino group and R2 is hydrogen or a halogen. 2-Phenyl-[1,2,4]triazolo[1,5-a]pyridine derivatives of formula I with their 1,2,4-triazole nucleus build the structural core of a great number of functionalized molecules in medicinal chemistry.

TRIAZOLOPYRIDINE COMPOUNDS

The invention is concerned with triazolopyridine compounds of formula (I) wherein R1, R2, R3 and R4 are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These

TRIAZOLOPYRIDINE COMPOUNDS

The invention is concerned with triazolopyridine compounds of formula (I), wherein R1, R2 , R3 and R4 are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. The